Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group)
Lorenz-Meyer H, Bauer P, Nicolay C, Schulz B, Purrmann J, Fleig WE, Scheurlen C, Koop I, Pudel V, Carr L
Scandinavian journal of gastroenterology · 125 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
- Consumo medido con
- No se indica
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 1996-01-01 · Scand J Gastroenterol · vol. 31 · número 8 · págs. 778–785
- Editorial
- Taylor & Francis
- Citado
- 211 citas · más que el 93% de estudios similares · 3.4× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 25 trabajos
- Acceso
- De pago
- Áreas de investigación
- Inflammatory Bowel Disease · Fatty Acid Research and Health · Gut microbiota and health
- Palabras clave
- Crohn's disease, omega-3 fatty acids, low-carbohydrate diet, remission maintenance, relapse prevention, CDAI, C-reactive protein, dietary adherence, prednisolone
- MeSH
- humans, crohn disease, prednisolone, dietary carbohydrates, fatty acids, omega-3, anti-inflammatory agents, combined modality therapy, remission induction, double-blind method, patient compliance, adult, aged, middle aged, female, male, statistics as topic
10 autores
- H. Lorenz‐Meyer
- Peter Bauer
- Claudia Nicolay
- Barbara Schulz
- Jochen Purrmann
- Wolfgang E. Fleig
- Christian Scheurlen
- Irmtraut Koop
- Volker Pudel
- Lisa Carr
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
There is no established therapy for maintaining remission in patients with Crohn's disease. Following different suggestions from the literature, two potential interventions for maintaining remission were tested against placebo, using either 5 g/day of a highly concentrated omega-3 fatty acid compound or a carbohydrate-reduced diet (84 g/day).
Methods
A total of 204 patients were recruited after they had had an acute relapse. After remission (CDAI < or = 150) was attained with steroid therapy, patients were randomized to receive either omega-3 fatty acids (n = 70), placebo (n = 65), or diet (n = 69). Low-dose prednisolone was given to all patients for the first 8 weeks of intervention. CDAI and an acute-phase protein (CRP) were used as criteria for a relapse.
Results
The proportion of patients without relapse within a year were similar in the placebo and active treatment group (intention-to-treat analysis: placebo, 30%; active treatment, 30%; protocol-adhering patients, 29% versus 28%). Patients did gain benefit (53%; p = 0.023) for as long as they maintained the diet. However, intention-to-treat analysis (diet group, 40%) did not show a noticeable difference when compared with placebo.
Conclusions
Omega-3 fatty acids did not show an effect on extending the remission in Crohn's disease. For the diet patients the question remains whether the noncompliant patients dropped out early because they sensed a relapse approaching or whether their condition deteriorated because they failed to comply with the diet.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.